Envoy Medical, Inc. (COCH) Form 8-K — Nov 5, 2026

$COCHForm 8-KItems 2.02, 9.01Filed Nov 5, 2026, 7:10 AM ET0001213900-26-116112Original filing

Envoy Medical (NASDAQ: COCH) reported Q3 2026 net revenue of $66K (up from $42K a year ago) and a net loss attributable to common stockholders of $5.24 million, or $0.50 per share, versus a $3.55 per-share loss in Q3 2025.

Key figures

Revenue: 66000
Revenue Yoy: +57% (Q3: $66K vs $42K year-ago quarter)
Total Assets: 19158000
Cash Position: 14570000
Granted patents: 97
Prior year q3 eps: -$3.55
R and d expense q3: $3,077K
Cnc word score 12mo: 53.2% vs 15.2% baseline
Pending patent applications: 35
Trial patients at 6mo followup: 56
Net loss attributable to common q3: -$5,240K

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $40.67/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.